DE60109359D1 - Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten - Google Patents
Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsartenInfo
- Publication number
- DE60109359D1 DE60109359D1 DE60109359T DE60109359T DE60109359D1 DE 60109359 D1 DE60109359 D1 DE 60109359D1 DE 60109359 T DE60109359 T DE 60109359T DE 60109359 T DE60109359 T DE 60109359T DE 60109359 D1 DE60109359 D1 DE 60109359D1
- Authority
- DE
- Germany
- Prior art keywords
- ferritine
- antibodies
- treatment
- cancer types
- specific cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0000718A FR2804027B1 (fr) | 2000-01-20 | 2000-01-20 | Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers |
FR0000718 | 2000-01-20 | ||
PCT/FR2001/000192 WO2001052889A1 (fr) | 2000-01-20 | 2001-01-19 | Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60109359D1 true DE60109359D1 (de) | 2005-04-21 |
DE60109359T2 DE60109359T2 (de) | 2006-04-13 |
Family
ID=8846119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60109359T Expired - Lifetime DE60109359T2 (de) | 2000-01-20 | 2001-01-19 | Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten |
Country Status (10)
Country | Link |
---|---|
US (2) | US7153506B2 (de) |
EP (1) | EP1165134B1 (de) |
JP (1) | JP2003520250A (de) |
AT (1) | ATE290881T1 (de) |
AU (1) | AU3556901A (de) |
CA (1) | CA2387383C (de) |
DE (1) | DE60109359T2 (de) |
ES (1) | ES2239126T3 (de) |
FR (1) | FR2804027B1 (de) |
WO (1) | WO2001052889A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0412890B8 (pt) | 2003-07-24 | 2021-05-25 | Innate Pharma | método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno |
EP1563851A1 (de) * | 2004-02-17 | 2005-08-17 | Yissum Research Development Company of the Hebrew University of Jerusalem | Verbindung eines Antikörpers mit einer kationischen Emulsion als Drogenlieferungs-System |
CA2575607C (en) | 2004-08-03 | 2017-07-11 | Innate Pharma | Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor |
GB0420566D0 (en) * | 2004-09-16 | 2004-10-20 | Sec Dep For Environment Food & | Assay method |
WO2007034479A2 (en) * | 2005-09-20 | 2007-03-29 | Yissum Research Development Company | Nanoparticles for targeted delivery of active agents |
GB0612825D0 (en) * | 2006-06-28 | 2006-08-09 | Iti Scotland Ltd | Analyte detection |
GB0616508D0 (en) * | 2006-08-18 | 2006-09-27 | Iti Scotland Ltd | Analyte manipulation and detection |
US20090053736A1 (en) * | 2007-08-21 | 2009-02-26 | Mattingly Phillip G | Homogeneous Chemiluminescent Immunoassay for Analysis of Iron Metalloproteins |
CA2696634A1 (en) * | 2007-09-19 | 2009-03-26 | Monoclonal Antibodies Therapeutics | Monoclonal antibodies against human acidic and basic ferritins and nucleotide and amino acid sequences thereof |
US8728477B2 (en) | 2007-09-19 | 2014-05-20 | Immune Pharmaceuticals Ltd. | Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5156840A (en) * | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
US5843440A (en) * | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
EP0627941A1 (de) * | 1992-02-28 | 1994-12-14 | ORDER, Stanley E. | VERWENDUNG VON AGGREGIERTEN PROTEINEN ZUR VERLäNGERUNG DER VERWEILDAUER EINES WIRKSTOFFES AM ZIELORT; WIE ZUM BEISPIEL BEI EINEM TUMOR |
-
2000
- 2000-01-20 FR FR0000718A patent/FR2804027B1/fr not_active Expired - Fee Related
-
2001
- 2001-01-19 EP EP01907655A patent/EP1165134B1/de not_active Expired - Lifetime
- 2001-01-19 ES ES01907655T patent/ES2239126T3/es not_active Expired - Lifetime
- 2001-01-19 AT AT01907655T patent/ATE290881T1/de not_active IP Right Cessation
- 2001-01-19 AU AU35569/01A patent/AU3556901A/en not_active Abandoned
- 2001-01-19 DE DE60109359T patent/DE60109359T2/de not_active Expired - Lifetime
- 2001-01-19 WO PCT/FR2001/000192 patent/WO2001052889A1/fr active IP Right Grant
- 2001-01-19 CA CA002387383A patent/CA2387383C/fr not_active Expired - Fee Related
- 2001-01-19 JP JP2001552936A patent/JP2003520250A/ja active Pending
- 2001-09-13 US US09/952,307 patent/US7153506B2/en not_active Expired - Lifetime
-
2006
- 2006-10-30 US US11/589,406 patent/US20070042447A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60109359T2 (de) | 2006-04-13 |
EP1165134A1 (de) | 2002-01-02 |
CA2387383A1 (fr) | 2001-07-26 |
ATE290881T1 (de) | 2005-04-15 |
FR2804027A1 (fr) | 2001-07-27 |
US7153506B2 (en) | 2006-12-26 |
EP1165134B1 (de) | 2005-03-16 |
CA2387383C (fr) | 2008-10-21 |
AU3556901A (en) | 2001-07-31 |
JP2003520250A (ja) | 2003-07-02 |
WO2001052889A1 (fr) | 2001-07-26 |
FR2804027B1 (fr) | 2002-08-30 |
ES2239126T3 (es) | 2005-09-16 |
US20070042447A1 (en) | 2007-02-22 |
US20020106324A1 (en) | 2002-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119353T1 (el) | Θεραπευτικη χρηση αντισωματων anti-cs1 | |
CY1107453T1 (el) | Baff, σχετικοι δεσμευτικοι παραγοντες και χρηση αυτων στη διεγερση και αναστολη β-κυτταρων και ανοσοσφαιρινων σε ανοσοαποκρισεις | |
DE69433406T2 (de) | Antikörper gegen cd40 | |
BR0011838A (pt) | Elementos misturadores estáticos empilhados | |
ATE177754T1 (de) | Fragmente von prion proteinen. | |
HUP0301877A2 (hu) | Aromatáz inhibitorok és monoklonális anti-HER2 ellenanyagok mint tumorellenes szerek | |
DK1565489T3 (da) | Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet | |
DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
DE69633717D1 (de) | Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis | |
PT1572087E (pt) | Anticorpos contra o antigénio de cancro tmeff2 e suas utilizações | |
BRPI0414513A (pt) | kid3 e anticorpos de kid3 que se ligam a ele | |
ATE419516T1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
DE60109359D1 (de) | Verwendung von anti-ferritin antikörper bei der behandlung von bestimmten krebsarten | |
ATE364396T1 (de) | Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern | |
GB9924957D0 (en) | Novel treatment | |
ES2098274T3 (es) | Anticuerpos monoclonales. | |
DE69622259T2 (de) | Cd40 bindendes protein zur stimulierung der immunantwort | |
DE60238987D1 (de) | Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper | |
WO2001071357A3 (en) | Diagnosis and treatment of breast cancer | |
DE69615843T2 (de) | Il-8 antagonisten zur behandlung von asthma | |
YU68602A (sh) | Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje | |
GB0004576D0 (en) | Proteins | |
DE602005025459D1 (de) | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |